NCT00256074

Brief Summary

The purpose of this study is to assess the impact of different feeding solutions on patients with breathing difficulty being supported by a breathing machine. The aim of the study is to determine if high fat-low carbohydrate feeding reduces the carbon dioxide production in patients with respiratory failure.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2004

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2004

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

November 17, 2005

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 21, 2005

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2007

Completed
Last Updated

April 12, 2017

Status Verified

April 1, 2017

Enrollment Period

3.4 years

First QC Date

November 17, 2005

Last Update Submit

April 10, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • To determine if high-fat low-carbohydrate enteral feeding reduces the carbon dioxide production and the respiratory quotient in patients with respiratory failure.

    patients will be followed until death or hospital discharge

Secondary Outcomes (1)

  • 1. If high-fat, low-carbohydrate enteral feeding reduces carbon dioxide production, dead space ventilation the number of days spent on mechanical ventilation,or the length of ICU stay, hospital length of stay or mortality.

    patients will be followed until death or hospital discharge

Study Arms (2)

Standard Therapy Group

OTHER

Standard therapy group. Will receive high carbohydrate, low fat enteral feeding, (16.7% protein, 30% fat and 53.3% carbohydrate). The target rate is determined by the treating physician and dietician, for a minimum of 5 days following randomisation.

Procedure: Enteral feeding formula

Alternative Therapy Group

OTHER

2.Alternative therapy group will receive high-fat, low carbohydrate enteral feeding, (16.7% protein, 55.2% fat and 28.1% carbohydrates. At a target rate determined by the treating physician and dietician, for a maximum of 5 days following randomisation.

Procedure: Enteral feeding formula

Interventions

Alternative Therapy GroupStandard Therapy Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patient, 18 years or older admitted with acute respiratory failure (PaO2/FiO2 \<300), needing mechanical ventilation. Are expected to be require mechanical ventilation for more than 48 hours.
  • Patients who are to receive enteral feeding via a gastric or post-pyloric feeding tube.
  • Patients or their next-of-kin consent to participate in the study. -

You may not qualify if:

  • Patients under the age of 18 years
  • Patients with contra-indications to enteral feeding
  • Patients receiving total parental nutrition
  • Patients who are already enrolled in another study that may influence the outcome of this study.
  • Patients who are not receiving active medical management or are expected to die within 24 hours at the time of study entry.
  • Patients with diabetes mellitus, renal failure or liver failure.
  • Patients or next-of-kin who do not consent to participate in the study. -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Intensive Care Unit, The Royal Melbourne Hospital,

Parkville, Victoria, 3050, Australia

Location

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Megan Robertson, MBBS

    Melbourne Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 17, 2005

First Posted

November 21, 2005

Study Start

June 1, 2004

Primary Completion

November 1, 2007

Study Completion

November 1, 2007

Last Updated

April 12, 2017

Record last verified: 2017-04

Locations